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Background/Aims: The role of signal transducer and activator of transcription 3 (Stat3) in liver ﬁbrosis is still
controversial. Since hepatic stellate cells (HSCs) and transforming growth factor-β1 (TGF-β1) are central to
the ﬁbrogenesis, our goal was to clarify the mechanism of Stat3 crosslinking of TGF-β1 signaling.
Methods: Stat3, TGF-β1 mRNA and protein expressions were examined in liver tissues of chronic hepatitis B
(CHB) patients and diethylinitrosamine (DEN)-induced rat ﬁbrosis model. The effect of Stat3 activation or
suppression on TGF-β1 signaling in HSCs was tested in vitro and in vivo.
Results: Stat3 expression as well as TGF-β1 was increased in CHB patients and DEN-induced ﬁbrosis rat model.
This was strongly correlated with increase in ﬁbrosis staging. TGF-β1, a mediator of ﬁbrosis, was enhanced by
Stat3, but suppressed by siRNA-mediated RNA knockdown of Stat3 (siStat3) or Janus kinase 2 inhibitor
(AG490) both in vivo and in vitro. Stat3 crosslinking TGF-β1 signaling plays an important role in HSC activation
and increasing ﬁbrosis related products. TGF-β1 could not achieve proﬁbrogenic cytokine and anti-apoptosis
characteristics without Stat3 activation in HSCs.
Conclusion:We provide a novel role of Stat3 cooperating TGF-β1 in activation and anti-apoptotic effect of HSCs.
Stat3 worsens liver ﬁbrosis through the up-regulation of TGF-β1 and ﬁbrotic product expression.© 2014 Elsevier B.V. All rights reserved.1. Introduction
Liver ﬁbrosis and its end stage cirrhosis represent the ﬁnal pathway
of chronic liver diseases [1]. Progression of liver ﬁbrosis is a dynamic
process, characterized by accumulation exceeding degradation of extra-
cellular matrix (ECM). Over the past two decades, sinusoidal resident
hepatic stellate cells (HSCs) have been recognized as the major source
of ECM. HSC activation and trans-differentiation into myoﬁbroblasts
are believed to be the key events in liver ﬁbrogenesis [2].
Transforming growth factor-β1 (TGF-β1) is considered a pivotal
proﬁbrogenic cytokine in the liver [2] and in vitro, TGF-β1 participates
in every step of HSC activation. TGF-β1 triggers phenotypical HSC
transdifferentiation from quiescence to activation by paracrine and
autocrine action, and directly induces collagen I (Col 1) expressionepatic stellate cells; TGF-β1,
, α-smooth muscle actin; Stat3,
us tyrosine kinase; GH, growth
ine; HBV, hepatitis B virus; AF,
munohistochemistry; IF, immu-
PCR, quantitative polymerase
rology, Shanghai First People's
Ning Road, Shanghai 200080,and α-smooth muscle actin (α-SMA) stress ﬁber organization [3,4].
TGF-β1 signals through transmembrane receptors consisting of
type I (TGF-βRI) and II (TGF-βRII) heterodimers to initiate downstream
signaling via Smad proteins, which modulate the transcription of target
genes, including those encoding ECM components, such as procollagen-I
and -III [5,6].
Signal transducer and activator of transcription 3 (Stat3) is a tran-
scription factor that is phosphorylated by Janus tyrosine kinases (Jak)
in response to cytokine activation which then dimerizes and moves
into the nucleus to activate transcription of cytokine-responsive genes.
Cytokines that activate Stat3 include growth hormone (GH), IL-6 family
cytokines, and G-CSF. Stat3 induces progression through the cell cycle,
prevents apoptosis and may be associated with cancer development.
Stat3 activation is detected virtually in all rodent models of liver injury
and in human liver diseases. However, the role of Stat3 pathway in
liver ﬁbrogenesis appears to be controversial. Due to the hepato-
protective and proliferative functions of Stat3, Stat3 in hepatocytes
plays a protective role in preventing liver ﬁbrosis [7–11]. Interestingly,
Stat3 plays a counteraction role in HSCs. Inhibition of the Stat3 pathway
induces apoptosis of HSC [12]. Mice devoid of Stat3 signaling in HSCs
(GFAPStat3−/−mice) are less susceptible to ﬁbrosis [13]. Stat3 pathway
mediates the promotional role of leptin in liver ﬁbrosis in mouse model
and is involved in leptin inhibition of SREBP-1c expression in HSCs
in vivo and in vitro [14]. Importantly, Ogata ﬁrst revealed that TGF-β1
is a target gene of Stat3 and Stat3 enhances hepatic ﬁbrosis through
2238 M.-Y. Xu et al. / Biochimica et Biophysica Acta 1842 (2014) 2237–2245upregulation of TGF-β1 in hepatocytes and in liver ﬁbrosis mice model
[15]. Kinjyo identiﬁed two Stat3-binding sites in the promoter region
of TGF-β1 and demonstrated that Stat3 activates the promoter activity
in T cells [16].
Given that to date no studies have deﬁned clearly the impact of Stat3
on TGF-β1 expression, we investigated possible molecular mechanisms
of Stat3 dependent TGF-β1 expression in HSCs. This hypothesis was
also tested in liver tissues of chronic hepatitis B (CHB) patients and
diethylinitrosamine (DEN) induced liver ﬁbrosis rat model. We also
examined whether TGF-β1/Smad signaling is activated by IL-6/Stat3.
2. Materials and methods
2.1. Experimental animal models
Seventy-ﬁvemale ﬁbrosisWistar ratsmodelwas induced bywatering
of 0.05 g/l diethylinitrosamine (DEN) daily. Thirty rats were administered
selective Janus kinase (Jak) 2 inhibitor tyrphostin AG490 (1 mg/kg/d)
intraperitoneally in ﬁrst week. Early ﬁbrosis (EF) rats were sacriﬁced
4 weeks after DEN watering and advanced ﬁbrosis (AF) rats were
sacriﬁced 8 weeks. Rats were then separated into 5 groups (Control:A
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Fig. 1. Stat3 and TGF-β1 expression in liver ﬁbrosis of CHB patients. Stat3, TGF-β1mRNA and pr
and qPCR. Patients were divided to 3 groups: Control, n=10; early ﬁbrosis (EF, liver ﬁbrotic sta
qPCRwere performed three times. (A) IH-stained liver tissues were taken from CHB patients w
expression; (d), (e), and (f) show TGF-β1 expression. (B) Stat3 and TGF-β1 mRNA expressi
comparing to EF, p = 1.25E− 05; TGF-β1: AF comparing to EF, p= 9.39E− 4). The correla
TGF-β1mRNA diagnosing AF stages were 0.783 and 0.692. (C) IF of (a) DAPI (blue), (b) p-Stat3
were stained with DAPI. (d) A small portion of p-Stat3 positive cells of portal area were foundn= 15; EF: n= 15; EF + AG490: DEN 4wk plus AG490 1wk, n= 15;
AF: n = 15; AF + AG490: DEN 8wk plus AG490 1wk, n = 15). These
studies were approved by the Ethical Committee of the Shanghai First
People's Hospital (Shanghai, China).
2.2. Cell culture and lentivirus
Primary HSCs were isolated from livers of Wistar rats and cultured
on plastic dishes in Dulbecco's modiﬁed Eagle's medium (DMEM;
Invitrogen, Carlsbad, CA), supplemented with 4 mmol/l L-glutamine,
10%FCS, and penicillin (100 IU/ml)/streptomycin (100 mg/ml). Primary
HSCswere treatedwith TGF-β1 (Miltenyi Biotec, Auburn, CA) at 2 ng/ml
or IL-6 at 10 ng/ml, respectively. Lentivirus encoding siRNA gene of
Stat3 for transduction (siStat3) and the control virus showed greenﬂuo-
rescent protein (GFP) expression in the cells (Microbix, Ontario,
Canada).
2.3. Patients and liver samples
All human liver tissues were obtained through percutaneous biopsy
of liver of patients at Shanghai First People's Hospital which includedS3
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ith liver ﬁbrotic stage of S0, S1, and S3 (×200magniﬁcation). (a), (b), and (c) show p-Stat3
ons were statistically up-regulated in AF compared to EF or Control patients (Stat3: AF
tion coefﬁcient of Stat3 and TGF-β1 mRNA was 0.413 (p= 0.003). AUROCs of Stat3 and
(green) and (c) TGF-β1 (red) in the liver of a CHB patient (liver ﬁbrotic stages: S3). Nuclei
to co-express TGF-β1 (see red frame).
2239M.-Y. Xu et al. / Biochimica et Biophysica Acta 1842 (2014) 2237–2245128 CHB patients (Suppl. Table 1) for microarray and 60 CHB patients for
qPCR (Suppl. Table 2). The procedure for human sample collection was
approved by the Ethics Committee of Shanghai First People's Hospital.
2.4. Immunohistochemistry (IH) and immunoﬂuorescence (IF) staining
Formaldehyde-ﬁxed, parafﬁn-embedded sections of liver tissue
were subjected to hematoxylin and eosin (H&E) staining and IH follow-
ing routine protocols as described. Antibodies were as follows: TGF-β1
(Santa Cruz Biotechnology) and p-Stat3 (Cell Signaling). IF double stain-
ing of human or rat liver tissue was incubated with human anti-p-Stat3
and anti-TGF-β1 (Invitrogen). IF staining ofα-SMA and vimentin (Vim)
was used to identify activated HSCs. Brieﬂy, cell slides were incubated
with anti-vim (Abcam, United Kingdom) and anti-α-SMA (Boster,
China) primary antibodies. 4′6-Diamidino-2-phenylindole (DAPI) was
applied to show the nucleus. Representative images were captured
with an Olympus IX70.
2.5. Quantitative polymerase chain reaction (qPCR) analysis
The qPCR was performed using SYBR Green PCR Kit (Applied
Biosystems, Foster City, CA) and ABI 7900HT Fast Real-Time PCR Systemb
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Fig. 2. Stat3 and TGF-β1 expression in DEN-induced liver ﬁbrosis rats. Stat3 and TGF-β1 mR
rats (EF: n = 15; AF: n = 15; Control: n = 15) by use of IH/IF staining and qPCR. IH, IF and
(×200magniﬁcation). (a), (b), and (c) showus p-Stat3 expression; (d), (e), and (f) show us TGF
AF than EF or Control rats [Stat3: AF (2.11 ± 0.14) comparing to EF (1.30 ± 0.39), p = 8.48
correlation coefﬁcient of Stat3 and TGF-β1 mRNA was 0.916 (p= 0.002). (C) IF of (a) DAPI (b
were stained with DAPI. A small portion of p-Stat3 positive cells were found to co-express TGF(Applied Biosystems). Another qPCR was performed using M-MLV1
PCR Kit (Promega) and TRI REAGENT® RNA System (Molecular
Research Center). The messenger RNA (mRNA) level of speciﬁc genes
was normalized against β-actin. Primers used are listed in Suppl.
Table 3.
2.6. Western blotting (WB)
Western blotting was performed using antibodies as follows:
p-Smad3 (Epitomics/Biomol); β-actin, survivin, ChK1 and Bcl2
(Sigma-Aldrich); α-SMA (Dako); E-Cad, TGF-β1, Caspase3 and GAPDH
(Santa Cruz Biotechnology); and p-Stat3, Stat3, p-Smad2, p-Smad1,
and Cleaved-Caspase3 (Cell Signaling). The secondary antibody was
an anti-rabbit antibody (BD Bioscience, 1:4000).
2.7. Cell apoptosis assays
Cells were washed with PBS and re-suspended in 500 μl binding
buffer containing 2 μl Annexin V-FITC. After incubation, the samples
were analyzed using ﬂow cytometry (FACSCalibur, BD Biosciences, San
Jose, CA).50um
Merge
B
R=0.916
P=0.002
p=8.48E-11
p=5.11E-10
NA and protein expression were examined in liver tissues of 45 DEN-induced ﬁbrosis
qPCR were performed three times. (A) IH-stained liver tissues were taken from rats
-β1 expression. (B) Stat3 and TGF-β1mRNA expressionswere statistically up-regulated in
E− 11; TGF-β1: AF (2.42 ± 0.17 comparing to EF (1.55 ± 0.18), p = 5.11E− 10]. The
lue), (b) p-Stat3 (green) and (c) TGF-β1 (red) in the liver of control rat and AF rat. Nuclei
-β1 (see red frame of AF rat liver).
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Cells were harvested after 48 h and ﬁxed in 70% ice-cold ethanol
overnight. The cells were then washed with PBS, and stained with
propidium iodide (50 mg/ml) in PBS supplemented with RNase
(50 mg/ml) in the dark at room temperature for 30min. Testswere per-
formed in triplicate for each sample, and analyses of cell cycle distribu-
tion were performed by ﬂow cytometer in accordance with the
manufacturer's guidelines (FACS, BD Bioscience, USA).
2.9. Statistical analysis
Results are expressed asmean±SE and the experimentwas repeated
three times. Data were analyzed using ANOVA test. A p value b0.05 was
considered statistically signiﬁcant.
3. Results
3.1. Up-regulation of Stat3 correlates with high expression of TGF-β1 in
human advanced liver ﬁbrosis
Total genomic proﬁles of liver tissues were compared in 7 controls
and 121 CHB patients (Fibrosis Scheuer score: S0–S4). Expression ofsi
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Fig. 3. IL-6/Stat3 and TGF-β1 interaction and IL-6/siStat3 inﬂuence activation of HSC. Rat primar
at 2 ng/ml or IL-6 at 10 ng/ml, respectively. Lentivirus encoding siRNA gene of Stat3 for transdu
the cells. WB graphs represent at least three independent experiments. (A) WB of HSCs treated
β-actin. *, compared to HSCs cultured for 0 h, p b 0.05. (a) a-SMA, E-Cad, STAT3, p-STAT3 and β-a
higher inHSCs treatedwith TGF-β1 at 24 h, 48 h, 72 h than 0 h [p-value of STAT3/p-STAT3: 24 h (7
2/3, a-SMA, E-Cad, Stat3, p-Stat3 andβ-actin levelswere detected in 4 groups ofHSCs (HSC, siStat3
groupHSCwere signiﬁcantly up-regulated at 12 h, 24 h, 48 h, and 72h compared to 0h [p-values: 1
HSC were signiﬁcantly up-regulated at 48 h, 72 h compared to 0 h [p-values: 48 h (5.08E− 4), 72
compared to0h in theHSCgroup [p-values: 3 h (0.049), 6 h (0.047), 12h (0.036), 24h (0.022), 48
h and 72 h compared to 0 h in the anti-TGF-β1-HSC group [p-values: 24 h (0.036), 48 h (2.11E−
tivating HSCs treated with IL-6 or siStat3 and untreated HSCs (Control) at 0 h, 6 h, 12 h, 24 h, 48TGF-β1 and Stat3 mRNA was signiﬁcantly higher in advanced ﬁbrosis
(AF, S3-S4) patients than in early ﬁbrosis (EF, S0–S2) patients with
microarray (Suppl. Fig. 1). To explore the inﬂuence of Stat3 on the
human liver ﬁbrosis, 60 liver samples of CHB patients (Control: 10; EF:
30; AF: 20) were collected. As expected, p-Stat3 and TGF-β1 positive
cells around hepatic portal area preferentially existed in AF livers
(Fig. 1A-c, f) and only a few of them were detected in EF livers
(Fig. 1A-b, e). Stat3 mRNA were scarcely expressed in normal and EF
livers but highly expressed in AF livers along with up-regulated TGF-
β1 (Fig. 1B). Furthermore, Stat3 levels were positively correlated with
TGF-β1 expression in AF livers (r = 0.413, p b 0.01) and AUROCs of
Stat3 and TGF-β1 for diagnosing of AF stages were 0.783 and 0.692
(Fig. 1B), which is further proof to the effect of Stat3 and TGF-β1 on
liver ﬁbrogenesis. As illustrated in Fig. 1C, a small portion of p-Stat3
positive cells of portal area were found to co-express TGF-β1 in the AF
liver of a CHB patient (Scheuer score: S3). These data suggested the
importance of Stat3 in the generation of liver ﬁbrosis in humans.
3.2. Hepatic p-Stat3 positive tissues exhibit high TGF-β1 expression and
aggravate ﬁbrosis characteristics in DEN-induced ﬁbrosis rat model
To explore the role of Stat3 inﬁbrogenesis,we examined the Stat3 sta-
tus in the livers of DEN-induced ﬁbrosis rats (EF: n = 15; AF: n = 15;24h                                                   48h                       72h  
                              siStat3-HSC                             Anti-TGFβ1-HSC               siStat3+Anti-TGFβ1-HSC    
0      3     6   12    24   48    72 0      3     6   12    24   48    72 0      3     6   12    24   48    72   48    72 
yHSCswere isolated and cultured for 0, 3, 6, 12, 24, 48, and 72 h. HSCs treatedwith TGF-β1
ction (siStat3) and the control virus showed green ﬂuorescent protein (GFP) expression in
with TGF-β1 for 0, 3, 6, 12, 24, 48, and 72 h were examined. The values represent ratio of
ctin fromHSC protein extracts treatedwith TGF-β1. STAT3/p-STAT3 levels were signiﬁcantly
.68E− 14/0.002), 48 h (5.47E− 16/0.029), 72 h (9.62E− 15/0.008)]. (b) TGF-β1, p-Smad1/
-HSC, anti-TGF-β1-HSCand siStat3+ anti-TGF-β1-HSC) treatedwith IL-6.①TGF-β1 levels in
2 h (0.046), 24h (0.038), 48h (2.45E−6), 72 h (1.38E−7)]. TGF-β1 levels in group siStat3-
h (6.77E− 5)].②p-Stat3 levels signiﬁcantly increased at 3 h, 6 h, 12 h, 24 h, 48 h, and 72 h
h (1.42E−2), and72h (6.30E−5)]. But p-Stat3 levels signiﬁcantly increasedonly at 24h, 48
2), and 72 h (1.07E− 2)]. (B) IF of GFP revealed morphology and number of quiescent/ac-
h and 72 h.
2241M.-Y. Xu et al. / Biochimica et Biophysica Acta 1842 (2014) 2237–2245Control: n = 15). The increasing level of p-Stat3 was in concomitance
with TGF-β1 in liver tissues stained by IH while liver ﬁbrosis grades
aggravated (Fig. 2A). Notably, expression of Stat3 mRNA also increased
during liver ﬁbrosis aggravation and closely correlated with the up-
regulation of TGF-β1 (Fig. 2B). More importantly, positive p-Stat3 tissues
of hepatic portal area in DEN-treated AF rats were found to co-express
TGF-β1, indicating that Stat3may acquire the feature of ﬁbrotic promoter
during ﬁbrogenesis (Fig. 2C). Considering the consistent results of human
ﬁbrogenesis, we speculated that the activated Stat3may undergo ﬁbrotic
transformation in AF liver, where the unique TGF-β1 exposure may play
an important role.
3.3. Stat3 can induce TGF-β1 up-regulation and plays an important role in
HSC activation
These ﬁndings prompted us to investigate whether there is a rela-
tionship between TGF-β1 signaling and Stat3 activation and to study
the functional importance of this toward their production in activated
HSCs. Rat primary HSCs responded to TGF-β1 treatment by expressingF-
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Fig. 4. Alteration of ﬁbrosis related products induced by IL-6/siStat3 or TGF-β1 in rat primary
treated with TGF-β1 at 2 ng/ml, IL-6 at 10 ng/ml, siStat3, GFP respectively. All graphs represen
in HSCs treated with TGF-β1, IL-6, or siStat3. Nuclei were stained with GFP (blue). (B) WB ana
extracts treatedwith GFP, siStat3, IL-6 and untreated Control. (C) RelativemRNA expression of S
*, compared to GFP HSCswith TGF-β1(−), p b 0.05; #, compared to GFPHSCswith TGF-β1(+),
statistically up-regulated compared to untreated GFP (p-values: 6.05E− 06, 0.016, 2.09E− 09
mRNA statistically down-regulated compared to GFP (p-values: 2.87E − 06, 6.96E − 05). H
statistically up-regulated compared to untreated GFP (p-values: 2.84E− 06, 2.61E− 04, 7.04E
TGF-β1, α-SMA, and Vim mRNA statistically different compared to untreated GFP (p-values: 3
TGF-β1, α-SMA, Vim, and Fn1 mRNA statistically down-regulated compared to TGF-β1 treated
TGF-β1 plus IL-6, TGF-β1, α-SMA, Fn1, and Col1a1 mRNA statistically up-regulated compared tostatistically higher levels of Stat3/p-Stat3 at 24, 48 and 72 h comparing
to 0 h (p b 0.05, Fig. 3Aa). Then we analyzed TGF-β1, p-Smad1/2/3,
Stat3/p-Stat3 levels in 4 groups of HSCs incubated with IL-6 [HSC,
Stat3 knock-down HSC (siStat3-HSC), HSC treated with blocking anti-
bodies of the TGF-β1 (anti-TGF-β1-HSC) and HSC treated both with
siStat3 and blocking antibodies of the TGF-β1 (siStat3 + anti-TGF-β1-
HSC)] at 0, 3, 6, 12, 24, 48 and 72 h. First, we observed up-regulation
of TGF-β1 upon Stat3/p-Stat3 challenge in HSCs prior to IL-6 induction
after 12 h (Fig. 3Ab). Secondly, up-regulation of TGF-β1 was only
observed in siStat3-HSCs prior to IL-6 induction after 48 h because of
cell activation by themselves (Fig. 3Ab). Thirdly, Stat3/p-Stat3 levels in-
creased among 3, 6, 12, 24, 48 and 72 h, TGF-β1 and p-Smad2/3 levels
signiﬁcantly increased among 12, 24, 48 and 72 h in HSCs. As inhibiting
TGF-β1 pathway, p-Stat3 levels were lower in anti-TGF-β1-HSC than
HSC (Fig. 3Ab). It is possible that some, but not all, of Stat3 phosphory-
lation are affected by TGF-β1. All of the above data showed that incuba-
tion of HSC with IL-6 increased TGF-β1 protein levels. The results led us
to propose that p-Stat3 mediates TGF-β1 up-regulation. Regardless
activation of TGF-β1 or Stat3, α-SMA levels gradually increased and+                         +
               - -
                - +
B WB of  HSCs
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HSCs. Rat primary HSCs were isolated and cultured for 48 h (A) and 12 h (B and C). HSCs
ted 3 independent experiments. (A) IF of α-SMA and Vimentin (green) and F-actin (red)
lyses of Stat3, p-Stat3, TGF-β1, a-SMA, E-Cad, p-Smad1/2/3, and GAPDH from HSC protein
tat3, TGF-β1,α-SMA, Vim, Fn1 and Col 1a1 inHSCs treatedwith IL-6/siStat3, TGF-β1 or not.
p b 0.05. HSCs barely treatedwith IL-6, Stat3, TGF-β1,α-SMA, Vim, Fn1, and Col1a1mRNA
, 1.47E− 04, 2.99E− 06, 5.69E− 06). HSCs only treated with siStat3, Stat3 and TGF-β1
SCs treated with IL-6 plus TGF-β1, Stat3, TGF-β1, a-SMA, Vim, Fn1, and Col1a1 mRNA
− 08, 1.39E− 05, 7.79E− 08, 1.57E− 06). HSCs treated with siStat3 plus TGF-β1, Stat3,
.16E− 06, 1.95E− 05, 6.33E− 06, 2.48E− 04). HSCs treated with TGF-β1 plus siStat3,
GFP (p-values: 1.61E− 05, 3.62E− 05, 6.00E− 03, 1.51E− 06). And HSCs treated with
TGF-β1 treated GFP (p-values: 0.001, 0.003, 0.010, 2.53E− 04).
2242 M.-Y. Xu et al. / Biochimica et Biophysica Acta 1842 (2014) 2237–2245E-Cad levels decreased. Most importantly,α-SMA and E-Cad expression
had an identical changing trend in HSCs accompanied with TGF-β1 or
Stat3 alteration (Fig. 3Aa and Ab). To further consolidate this result, IF
analysis revealed that rat primary HSCs treated with IL-6 activated
more excessively and earlier than controls in 24 h (Fig. 3B). On the
contrary, rat primaryHSCs treatedwith siStat3maintained their inactiv-
ity at 24, 48 and 72 h (Fig. 3B). These results imply that the Stat3-
mediated signaling pathway could induce TGF-β1 up-regulation and is
pivotal in HSC activation.
3.4. The increasing ﬁbrosis related products effect of Stat3 crosslinking
TGF-β1 signaling can be abolished in rat primary HSCs treated with
siStat3
We next intervened with IL-6, siStat3 or TGF-β1 in rat primary HSCs
to clarify the change of ﬁbrosis related products. IF analysis illustrated
that cytoplasmic α-SMA and Vim were dramatically increased in IL-6
or TGF-β1 treated cells compared to untreated cells, and they reached
themaximumextent in IL-6 plus TGF-β1 treated cells (Fig. 4A). Interest-
ingly, cytoplasmic α-SMA and Vim were negatively expressed with
siStat3 treatment and the effect was unchangeable with TGF-β1 plus
siStat3 treatment (Fig. 4A). This implies that TGF-β1-mediated ﬁbrosisb:
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Fig. 5. Effect of siStat3 or TGF-β1 on apoptosis of HSCs. Rat primary HSCswere isolated and cult
treated by siStat3 or TGF-β1were studied byWB and qPCR. Graphs represent at least three inde
parison of siStats (−) HSCswith TGF-β1(+) p b 0.05. (A)Maps of cell cycle (a) and apoptosis (b
G0/G1, S, G2/M phase of the cell cycle were shown (a). Apoptotic rate of HSCs treated with siSt
survivin, ChK1, Bcl2 and GAPDH from HSC protein extracts treated with GFP, siStat3, TGF-β1 an
Bcl2 in HSCs treated with siStat3 or TGF-β1.related products exportation might be, at least partially, involved in
HSCs upon Stat3 intervention. To further test the hypothesis, expres-
sions ofﬁbrosis related productswere studied in rat primaryHSCs treat-
ed with siStat3, IL-6 and TGF-β1 respectively at 12 h. After induction of
IL-6with HSCs, the levels ofα-SMA and p-Smad1/2/3were signiﬁcantly
higher and E-Cad were signiﬁcantly lower in them than in control cells
and siStat3 treated cells (p b 0.05, Fig. 4B). After induction of IL-6 or
TGF-β1 or IL-6 plus TGF-β1 with cells, the mRNA expression of 4
ﬁbrosis related genes was signiﬁcantly higher than untreated control
cells (p b 0.05; Fig. 4C). Of note, while IL-6 plus TGF-β1 treatment
signiﬁcantly enhanced the expression of 3 genes than TGF-β1 treated
cells (α-SMA, Fn 1 and Col 1a1: p b 0.05; Fig. 4C). Such effects were
not seen in siStat3 treated cells (Fig. 4C). Most importantly, inhibition
of Stat3 counterworked the proﬁbrotic effect in TGF-β1 plus siStat3
treated cells compared to TGF-β1 treated cells (α-SMA, Vim and Fn 1,
p b 0.05, Fig. 4C). Therefore TGF-β1 could not achieve proﬁbrogenic
cytokine effect without Stat3 activation in HSCs. We also showed that
siStat3 does not affect the mRNA levels of TGF-β1 in HSCs, but siStat3
attenuates the pro-ﬁbrogenic effect of TGF-β1 on the expression of
ﬁbrotic genes at 48 h (Suppl. Fig. 2). It indicated that Stat3 activation
mediates TGF-β1 signaling (Stat3 appears to be required not only up-
stream but also downstream TGF-β1).+
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pendent experiments. *, comparison of siStats (−) HSCswith TGF-β1(−) p b 0.05; #, com-
) on rat primaryHSCs treatedwith siStat3 or TGF-β1were analyzed. Percentages of cells in
at3/TGF-β1 was shown (c). (B) WB analyses of Stat3, p-Stat3, caspase3, cleaved-caspase3,
d untreated Control. (C) Relative mRNA expression of Stat3, caspase3, survivin, ChK1, and
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To explain Stat3 effect on cell proliferation or apoptosis of rat prima-
ry HSCs, apoptosis studies and expression of apoptosis related factors
were examined. Our data found that cells exhibited robust proliferation
ability and apoptosis was signiﬁcantly reducedwhenHSCswere treated
with TGF-β1 (Fig. 5Ab). The percentage of cells in the G0/G1 phase of
the cell cycle decreased and the G2/M phase increased in TGF-β1 treat-
edHSCs compared to untreatedHSCs (p-values: G0/G1: 4.90E− 04;G2/
M: 1.31E− 03; Fig. 5Aa). The percentage of apoptotic cells decreased
extremely in TGF-β1 treated HSC compared to untreated HSCs (p =
0.01E − 04, Fig. 5Ac). Anti-apoptotic proteins and mRNA (Bcl2 and
Survivin) were signiﬁcantly higher and pro-apoptotic protein and
mRNA (caspase3) were apparently lower in TGF-β1 treated HSCs than
in untreated cells [p-values of qPCR: Bcl2 (0.012), Survivin (0.023),
Caspase (1.67E − 03), Fig. 5B/C]. While apoptosis dramatically in-
creased (Fig. 5Ab) and percentage of cells in the G0/G1 phase of the
cell cycle signiﬁcantly increased and S phase decreased in siStat3 treat-
edHSCs compared to untreated, TGF-β1 and TGF-β1 plus siStat3 treatedEarly Fibrosis(4w)                                     Advance
AG490 - +                                    -
A
b
f
ca
e g
C   Serum ALT Levels of Rats D    Protein Exp
*
*
*
*
*
*
Fig. 6. AG490 treatment attenuates DEN-induced liver ﬁbrosis of rats. TGF-β1 and p-Stat3 prote
AG490 or not. Serum ALT levels, liver ﬁbrosis products, inﬂammation and ﬁbrosis scores were e
4 weeks + AG490 1 week), n= 15; AF (DEN 8 weeks), n= 15; and AF+ AG490 (DEN 8 wee
AG490(+) rats compared to AG490(−) rats, p b 0.05. (A) IH-stained liver tissues were taken f
and (h) showTGF-β1 expression. (B) Protein levels of p-Stat3 and TGF-β1were shown. (C) Seru
of Col1a1, Acta2, Mmp2 and Timp1 were shown. (E) Inﬂammation and ﬁbrosis scores of AG
positively stained by Sirius Red and H&E.HSCs (p-values: G0/G1: 2.04E− 02, 1.97E− 03, 3.88E− 02; S: 0.007,
4.10E− 03, 0.046, Fig. 5Aa). The percentage of apoptosis cells increased
in siStat3 treated HSC compared to untreated cells (p= 0.016, Fig. 5Ac).
Anti-apoptotic proteins and mRNA (Bcl2 and Survivin) were lower and
pro-apoptotic protein and mRNA (caspase3) were higher in siStat3
treated HSCs than untreated ones [p-values of qPCR: Bcl2 (0.026),
Survivin (0.022), Caspase (5.37E− 5), Fig. 5B/C]. The results showed
that siStat3 had a pro-apoptotic function and TGF-β1 had an anti-
apoptotic function. Importantly, apoptosis increased (Fig. 5Ab) and
percentage of cells in G0/G1 phase of the cell cycle increased in
siStat3 plus TGF-β1 treated HSCs compared to TGF-β1 treated HSCs
(p-values: G0/G1: 0.019, Fig. 5Aa). Percentage of apoptotic cells
increased in siStat3 plus TGF-β1 treated HSC compared to TGF-β1
treated cells (p = 0.021, Fig. 5Ac). Anti-apoptotic proteins and mRNA
(Bcl2 and Survivin)were lower in siStat3 plus TGF-β1 treated HSC com-
pared TGF-β1 treated cells [p-values of qPCR: Bcl2 (1.15E − 04),
Survivin (0.001), Fig. 5B/C]. So siStat3 could counteract the anti-
apoptotic effect of TGF-β1 in HSCs. These results imply that TGF-β1
maybe could not achieve suppressing apoptosis characteristics without
Stat3 participation in rat primary HSCs.d Fibrosis(8w) 
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in levels were examined in liver tissues of 60 DEN-induced liver ﬁbrosis rats treated with
valuated. Rats were divided into 4 groups: EF (DEN 4 weeks), n= 15; EF+ AG490 (DEN
ks + AG490 1 week), n= 15. WB and IH experiments performed 3 times. *, treatment of
rom rats (×200 magniﬁcation). (a), (b), (c), and (d) show p-Stat3 expression; (e), (f), (g),
mALT levelswere examined at 24 h and 48h after DEN treatment of rats. (D) Protein levels
490 treated and untreated rats. Fibrosis scores are based on the percentage of liver area
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AG490 was used to inhibit Stat3 activation. To evaluate whether
suppressing Stat3 has an effect on liver ﬁbrogenesis crosslinking
of TGF-β1, Wister rats were separated into 4 groups (EF: n = 15;
EF + AG490: n = 15; AF: n = 15; AF + AG490: n = 15). Liver
ﬁbrosis and inﬂammation were demonstrated by H&E and Masson
staining (data not shown). IH analysis (Fig. 6A) showed that the pro-
motional role of Stat3 and TGF-β1 in liver ﬁbrogenesis (EF and AF)
was strongly inhibited by interrupting Stat3 pathway (EF + AG490
and AF + AG490) in such model. To further conﬁrm the results,
levels of p-Stat3, TGF-β1 and ﬁbrosis related proteins (Col 1a1,
Acta2, Mmp2 and Timp1) were directly examined by WB analysis.
The p-Stat3 and TGF-β1 levels were signiﬁcantly higher in AF rats
than in the EF ones; while they were dramatically decreased in
AG490 treated EF or AF rats than untreated ones [p-value: p-Stat3
(AF) 0.006; p-Stat3 (EF) 0.005; TGF-β1 (AF) 0.018; TGF-β1 (EF)
0.009; Fig. 6B]. ALT levels were signiﬁcantly lower in AG490 treated
EF or AF rats compared to the untreated ones at 48 h [p-value: EF
(24 h) 0.002; EF (48 h) 0.005; AF (24 h) 0.006; AF (48 h) 0.002;
Fig. 6C). The levels of Acta2, Mmp2 and Timp1 were signiﬁcantly de-
creased in AG490 treated EF rats (p-value: 0.007; 0.029; 0.027;
Fig. 6D). The levels of Col1a1, Mmp2 and Timp1 were also signiﬁ-
cantly decreased in AG490 treated AF rats (p-value: 0.002; 0.010;
0.005; Fig. 6D). Liver inﬂammation scores revealed less vacuolated
cells and signiﬁcantly improved portal inﬂammation in the AG490
treated EF and AF rats compared to untreated ones [p-value: EF
(0.015); AF (0.042); Fig. 6E]. The levels of ﬁbrosis scores were also
signiﬁcantly reduced in AG490 treated AF rats [p-value: AF (0.021);
Fig. 6E]. These results suggested that Stat3 signaling might mediate
the promotional role of TGF-β1 in liver ﬁbrogenesis, especially in
advanced ﬁbrotic stages.
Finallywe included the schematic diagram illustrating the hypothet-
ical model that activation of the TGF-β1 pathway by IL-6/Stat3 leads to
aggravating ﬁbrosis (Fig. 7).IL-6/Stat3
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Fig. 7. Schematic diagram of TGF-β1 pathway crosslinkingwith Stat3 inHSCs exacerbating liver
inhibits HSC apoptosis, increases HSC activation and aggravates ﬁbrosis.4. Discussion
Threemain kinds of cytokines have been identiﬁed as being involved
in Stat3 activation in HSCs. Leptin or IL-6 stimulates the activation of
Stat3 and increases collagen mRNA expression in HSCs and subse-
quently accelerates liver ﬁbrosis [17]. While GH mediated suppres-
sion of ﬁbrosis may be due to inhibition of Stat3 and TGF-β1
production in Ito cells [15]. However, cross-talking of Stat3 and
TGF-β1 signaling in HSCs and ﬁbrogenesis has not been explained
clearly. It is also an issue to understand which type of cells plays a
major role in Stat3-mediated TGF-β1 production and ﬁbrosis. A com-
plex interplay between hepatic cell types takes place during hepatic
ﬁbrogenesis [18]. Activated HSCs secrete inﬂammatory chemokines,
express cell adhesionmolecules, andmodulate the activation of lym-
phocytes [19]. Damaged hepatocytes and inﬂammatory cells stimu-
late ﬁbrogenic actions and activate HSCs to secrete collagen [20,
21]. Therefore, a vicious circle in which ﬁbrogenic and target cells
stimulate each other is likely to occur.
We demonstrate the consistency of up-regulation of Stat3 and TGF-
β1 mRNA in advanced ﬁbrosis stages of CHB patients and DEN-induced
liver ﬁbrosis rat model. Rat model of DEN inducing liver ﬁbrosis was
selected in our study. This kind of rat model can imitate entire natural
history of chronic liver disease from liver ﬁbrosis, cirrhosis to carcino-
genesis. DEN is a toxic chemical causing oxidative injury on liver and
subsequently the oxidative damage hepatocytes that can activate
Stat3 in HSCs. So DEN induced liver ﬁbrosis rats can be used to better
understand the mechanisms of Stat3. IH and IF staining of liver tissues
identiﬁed p-Stat3 and TGF-β1 highly positive expression in parenchy-
mal and nonparenchymal cells, especially associated with advanced ﬁ-
brosis stages. AG490 treatment signiﬁcantly attenuates DEN-induced
chronic liver injury and ﬁbrosis, associated with and dependent on sup-
pressing Stat3. These results showed that activation of Stat3 crosslinking
of TGF-β1 exacerbates liver injury andﬁbrosis both inCHBpatients and in
DEN-induced liver ﬁbrosis rats. It may be concluded that TGF-β1 and
Stat3 reciprocally regulate liver damages, ﬁbrosis, and their expression
in human and rat liver ﬁbrosis.β1/Smad
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2245M.-Y. Xu et al. / Biochimica et Biophysica Acta 1842 (2014) 2237–2245Our ﬁnding of a direct induction of TGF-β1 by active Stat3 may pro-
vide another mechanism for the contribution of Stat3 to ﬁbrogenesis.
We also conﬁrmed that IL-6-mediated up-regulation of TGF-β1 mRNA
levels was suppressed by siStat3 in HSCs. Therefore, hyper-activation
of Stat3 in HSCs may contribute toward enhanced production of TGF-
β1. The increasing ﬁbrosis related product effect of Stat3 crosslinking
TGF-β1 signaling can be abolished in siStat3 treated HSCs. Morphologi-
cal studies proved that HSCs lacking Stat3 remain inactivated, even if
they were secondly added TGF-β1 treatment. These data suggest that
Stat3 directly up-regulates TGF-β1 expression at the transcriptional
levels in HSCs. So our study adds a new target, TGF-β1, to the list of
Stat3-regulated genes involved in ﬁbrogenesis.
Stat3 in HSCs appear to have a deteriorating role in liver ﬁbrosis
[12–14]. We used siStat3 to demonstrate that suppressing Stat3 pro-
motes apoptosis of HSCs. In non-stimulated HSCs, Stat3 is in its inactive
form and locates in the cytoplasm of hepatocytes. The binding of Stat3-
related cytokines to their receptors activates the receptor-associated
Jak, which phosphorylates Stat3. The resultant p-Stat3 dimers translo-
cate to the nuclei and function as transcriptional factors for downstream
genes including bcl-2, caspase3 and survivin that play important roles in
promoting HSC survival and an anti-apoptotic effect. And the results
illustrated that siStat3, having pro-apoptotic function, could withstand
the anti-apoptotic effect of TGF-β1 in HSCs. Our results also imply that
TGF-β1 could not achieve anti-apoptosis characteristics without Stat3
participation in HSCs.
Although the study ofWang has an opinion that activation of hepatic
Stat3 in the early stage of liver injury is likely to play an important role
in protecting against hepatocyte death andDNA damage, thereby acting
as a tumor suppressor to prevent liver tumorigenesis [22]. Our results
in vitro indicated that HSCs treated with IL-6 activate TGF-β1 and
have pro-ﬁbrotic function earliest in 6 h of cell incubation. Stat3 cross-
talking to TGF-β1 also aggravated the ﬁbrogenesis at early or mild
stage of liver ﬁbrosis both in CHB patients and in DEN treated rats. So
we chose AG490 as an anti-ﬁbrotic drug at an early stage but not late
stage. Early administration of AG490 is proved efﬁcient in reversing
hepatitis and liver ﬁbrosis in DEN induced liver ﬁbrosis rats. We
assumed that suppression of Stat3 activation in the early stage of liver
ﬁbrosis could be useful for preventing the progress of ﬁbrotic disease.
In conclusion, we provide a novel role for Stat3 cooperating in the
activation of TGF-β1 and in the anti-apoptotic effect of HSCs. Stat3 en-
hances liver ﬁbrosis through the up-regulation of TGF-β1 and ﬁbrotic
product expression. This study provides the basis for the therapeutic po-
tential Stat3 antagonists in the treatment of liver ﬁbrosis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbadis.2014.07.025.
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